Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland
Swiss Med Wkly
.
2024 Oct 3:154:3958.
doi: 10.57187/s.3958.
Authors
Maria Trottmann
1
,
Eva Blozik
1
,
Marcel Hilbig
2
,
Mark Pletscher
,
Niklaus Meier
3
Affiliations
1
SWICA Krankenversicherung AG, Winterthur, Switzerland.
2
ÖKK Kranken- und Unfallversicherungen AG, Landquart, Switzerland.
3
Berner Fachhochschule, Institut für Gesundheitsökonomie und Gesundheitspolitik, Bern, Switzerland.
PMID:
39465331
DOI:
10.57187/s.3958
Abstract
No abstract available.
Publication types
Letter
MeSH terms
Health Expenditures / statistics & numerical data
Humans
Immunotherapy, Adoptive / economics
Immunotherapy, Adoptive / methods
Lymphoma, Large B-Cell, Diffuse* / mortality
Lymphoma, Large B-Cell, Diffuse* / therapy
Switzerland